Relay Therapeutics reported Phase 2 efficacy data for zovegalisib (RLY-2608) in patients with PIK3CA-driven vascular anomalies, reporting a 60% volumetric response. The company framed the readout as beating expectations and positioning the isoform-selective PI3Kα inhibitor for a broader development path beyond oncology combinations. The update strengthens the case for vascular anomalies as a commercially relevant second indication and aligns with Relay’s broader late-stage strategy for PIK3CA-mutated populations, where VAs represent an additional clinical frontier with limited treatment options. In parallel, Relay’s broader program momentum is already reflected in prior reporting, but the new Phase 2 signal provides near-term validation for clinical prioritization and partner interest. The market reaction described in the coverage underscores how single-readout data can re-rate a diversified pipeline. For biotech stakeholders, the key is the same as always: proof of on-target pathway engagement translated into measurable anatomical response in a rare disease population.